Focus: Noven Pharmaceuticals is a specialty pharmaceutical company founded in 1999 focused on small-molecule transdermal delivery systems, headquartered in Miami, Florida. The company generates 71% of revenue from a single product (COMBIPATCH), indicating a highly concentrated portfolio.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Hot — 143 jobs added in 30d
Net +126 (143 new, 17 removed). Aggressive expansion phase.
Viable for specialists seeking deep transdermal/delivery experience or pipeline exposure, but carry elevated restructuring risk due to product concentration and modest hiring trajectory.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Represents 71% of company revenue; approaching loss of exclusivity presents major business inflection point.
Help build intelligence for Noven Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Noven Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
ANDA-track product in pre-launch phase; represents opportunistic generic/transdermal extension.
Post-LOE ANDA product; generic/mature asset with limited differentiation.
Post-LOE ANDA; generic formulation with no revenue visibility.
NDA-track product approaching LOE; niche dental anesthetic with limited market size.
Post-LOE ANDA opioid patch; legacy asset in mature/generic market.
6 discontinued, 3 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo